Intrahepatic cholangiocarcinoma

Kimberly M. Brown; Abhishek D. Parmar; David A. Geller

doi:10.1016/j.soc.2013.10.004

Intrahepatic cholangiocarcinoma

Kimberly M. Brown, Abhishek D. Parmar, David A. Geller

Research output: Contribution to journal › Review article › peer-review

43 Scopus citations

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a rare tumor, with an increasing incidence worldwide and an overall poor prognosis. Symptoms are usually nonspecific, contributing to an advanced tumor stage at diagnosis. The staging system for ICC has recently been updated and is based on number of lesions, vascular invasion, and lymph node involvement. Complete surgical resection to negative margins remains the only potentially curable treatment for ICC. Gemcitabine-based adjuvant therapy can be offered based on limited data from patients with unresectable ICC. Overall 5-year survivals after resection range from 17% to 44%, with median survivals of 19 to 43months.

Original language	English (US)
Pages (from-to)	231-246
Number of pages	16
Journal	Surgical Oncology Clinics of North America
Volume	23
Issue number	2
DOIs	https://doi.org/10.1016/j.soc.2013.10.004
State	Published - Apr 2014
Externally published	Yes

Keywords

Bile duct neoplasms
Cholangiocarcinoma
Intrahepatic bile duct cancer
Intrahepatic cholangiocarcinoma
Peripheral cholangiocarcinoma

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.soc.2013.10.004

Cite this

@article{ec3dee42456d4abd9333b100d7d08e1f,

title = "Intrahepatic cholangiocarcinoma",

abstract = "Intrahepatic cholangiocarcinoma (ICC) is a rare tumor, with an increasing incidence worldwide and an overall poor prognosis. Symptoms are usually nonspecific, contributing to an advanced tumor stage at diagnosis. The staging system for ICC has recently been updated and is based on number of lesions, vascular invasion, and lymph node involvement. Complete surgical resection to negative margins remains the only potentially curable treatment for ICC. Gemcitabine-based adjuvant therapy can be offered based on limited data from patients with unresectable ICC. Overall 5-year survivals after resection range from 17% to 44%, with median survivals of 19 to 43months.",

keywords = "Bile duct neoplasms, Cholangiocarcinoma, Intrahepatic bile duct cancer, Intrahepatic cholangiocarcinoma, Peripheral cholangiocarcinoma",

author = "Brown, {Kimberly M.} and Parmar, {Abhishek D.} and Geller, {David A.}",

year = "2014",

month = apr,

doi = "10.1016/j.soc.2013.10.004",

language = "English (US)",

volume = "23",

pages = "231--246",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - Intrahepatic cholangiocarcinoma

AU - Brown, Kimberly M.

AU - Parmar, Abhishek D.

AU - Geller, David A.

PY - 2014/4

Y1 - 2014/4

N2 - Intrahepatic cholangiocarcinoma (ICC) is a rare tumor, with an increasing incidence worldwide and an overall poor prognosis. Symptoms are usually nonspecific, contributing to an advanced tumor stage at diagnosis. The staging system for ICC has recently been updated and is based on number of lesions, vascular invasion, and lymph node involvement. Complete surgical resection to negative margins remains the only potentially curable treatment for ICC. Gemcitabine-based adjuvant therapy can be offered based on limited data from patients with unresectable ICC. Overall 5-year survivals after resection range from 17% to 44%, with median survivals of 19 to 43months.

AB - Intrahepatic cholangiocarcinoma (ICC) is a rare tumor, with an increasing incidence worldwide and an overall poor prognosis. Symptoms are usually nonspecific, contributing to an advanced tumor stage at diagnosis. The staging system for ICC has recently been updated and is based on number of lesions, vascular invasion, and lymph node involvement. Complete surgical resection to negative margins remains the only potentially curable treatment for ICC. Gemcitabine-based adjuvant therapy can be offered based on limited data from patients with unresectable ICC. Overall 5-year survivals after resection range from 17% to 44%, with median survivals of 19 to 43months.

KW - Bile duct neoplasms

KW - Cholangiocarcinoma

KW - Intrahepatic bile duct cancer

KW - Intrahepatic cholangiocarcinoma

KW - Peripheral cholangiocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84896739429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896739429&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2013.10.004

DO - 10.1016/j.soc.2013.10.004

M3 - Review article

C2 - 24560108

AN - SCOPUS:84896739429

SN - 1055-3207

VL - 23

SP - 231

EP - 246

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 2

ER -

Intrahepatic cholangiocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this